Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.64, $0.42 better than the analyst estimate of $0.22. Revenue for the quarter came in at $401.3 million versus the consensus estimate of $383 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.